PPAR‐γ Agonists and Their Effects on IGF‐I Receptor Signaling: Implications for Cancer
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
It is now well established that the development and progression of a variety of human malignancies are associated with dysregulated activity of the insulin‐like growth factor (IGF) system. In this regard, promising drugs have been developed to target the IGF‐I receptor or its ligands. These therapies are limited by the development of insulin resistance and compensatory hyperinsulinemia, which in turn, may stimulate cancer growth. Novel therapeutic approaches are, therefore, required. Synthetic PPAR‐γ agonists, such as thiazolidinediones (TZDs), are drugs universally used as antidiabetic agents in patients with type 2 diabetes. In addition of acting as insulin sensitizers, PPAR‐γ agonists mediate in vitro and in vivo pleiotropic anticancer effects. At least some of these effects appear to be linked with the downregulation of the IGF system, which is induced by the cross‐talk of PPAR‐γ agonists with multiple components of the IGF system signaling. As hyperinsulinemia is an emerging cancer risk factor, the insulin lowering action of PPAR‐γ agonists may be expected to be also beneficial to reduce cancer development and/or progression. In light of these evidences, TZDs or other PPAR‐γ agonists may be exploited in those tumors “addicted” to the IGF signaling and/or in tumors occurring in hyperinsulinemic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 1×
“As we have already mentioned in the previous section (the IGF system signaling pathways) the MAPK cascade transmits proliferative signals generated by cell surface receptors and cytoplasmic elements to the nucleus [152, 153].”
BackgroundGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“IGFBPs-1– 4 have similar affinities for IGF-I and IGF-II whereas IGFBP5 and 6 bind IGF-II with a 10- and 100-fold higher affinity, respectively, than IGF-I [34–36].”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Insulin, Insulin-Like Growth Factors and Colon Cancer: A Review of the Evidence
Giovannucci, E. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.11.3109s · Cited by 959
AMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426
Kimura, N., Tokunaga, C., Dalal, S., Richardson, C., Yoshino, K., Hara, K., Kemp, B. E., Witters, L. A., Mimura, O., & Yonezawa, K. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00615.x · Cited by 372
Elevated insulin receptor content in human breast cancer
Papa, V, Pezzino, V, Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G. B., Brand, R., Goldfine, I. D., & Vigneri, R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114868 · Cited by 338 · cited 1×
“Both IRS proteins and Shc compete for the same phosphosites on the receptor transmembrane domain [55].”
BackgroundSelf-citationBurstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024038127156 · Cited by 228 · cited 2×
“Moreover, TZDs, as other PPAR-γ agonists, such as the prostanoid 15d-PGJ2 [9], induce a variety of favorable changes (growth arrest, apoptosis, and/or partial redifferentiation) in several malignancies, including liposarcoma, and cancers of the breast, colon, pancreas, and prostate [10–18].”
Background
Cited by
Phytol: A review of biomedical activities
Islam, M. T., Ali, E. S., Uddin, S. J., Shaw, S., Islam, M. A., Ahmed, M. I., Chandra Shill, M., Karmakar, U. K., Yarla, N. S., Khan, I. N., et al. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.08.032 · Cited by 490
The role of chalcones in suppression of NF-κB-mediated inflammation and cancer
Yadav, V. R., Prasad, S., Sung, B., & Aggarwal, B. B. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.12.006 · Cited by 339
Age-associated chronic diseases require age-old medicine: Role of chronic inflammation
Prasad, S., Sung, B., & Aggarwal, B. B. (2012) · Preventive Medicine · doi:10.1016/j.ypmed.2011.11.011 · Cited by 290
Diabetes and Alpha Lipoic Acid
Golbidi, S., Badran, M., & Laher, I. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00069 · Cited by 270
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Metadata
- Authors
- Belfiore, A., Genua, M., & Malaguarnera, R.
- Venue
- PPAR Research
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 2009
- Issue
- 1
- Pages
- 830501-830501
- ISSN
- 1687-4757 (ISSN-L)
- 1687-4765
- OpenAlex
- W1964286374
- Cited by
- 115
- References
- 13
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.